Donn Casale reports a stock award at ARS Pharmaceuticals
By AlphaYouPublished Form 4
Casale Donn
Reporting filer
Donn Casale reports a stock award, not an open-market purchase or sale, in ARS Pharmaceuticals, Inc.. Form 4 filed Oct 5, 2026 lists 1 entry.
- Disclosed
- Oct 5, 2026
Reported details
1 entry| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) (derivative) | Casale Donn | 2026-10-01 | A | Grant or award | 1036923 | 0 | 1,036,923 | 4 days | Filed terms
|
Stock Option (right to buy) (derivative)
- Owner
- Casale Donn
- Date
- 2026-10-01
- Code
- A
- Action
- Grant or award
- Quantity
- 1036923
- Price
- 0
- Following holdings
- 1,036,923
- Reporting delay
- 4 days
- Filed terms and references
Filed terms
- security Title: Stock Option (right to buy)
- conversion Or Exercise Price: 4.12
- transaction Date: 2026-10-01
- transaction Form Type: 4
- transaction Code: A
- equity Swap Involved: 0
- transaction Shares: 1036923
- transaction Price Per Share: 0
- transaction Acquired Disposed Code: A
- id: F1
- expiration Date: 2036-09-30
- underlying Security Title: Common Stock
- underlying Security Shares: 1036923
- shares Owned Following Transaction: 1036923
- direct Or Indirect Ownership: D
- nature Of Ownership:
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- Casale Donn: President and CEO, Director.
- F1: 25% of the shares subject to the option vest on July 7, 2027, and the remaining shares will vest monthly thereafter over three years.
Original sources
Prepared automatically from public filing data. Report a correction.